|
Delayed
NSE India S.E.
07:48:15 17/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 2,616.60 INR | -0.62% |
|
-2.25% | +28.58% |
| 11-09 | Acucort signs exclusive agreement for Zeqmelit in Canada - launch expected in 2028 | FW |
| 11-06 | Glenmark Pharmaceuticals Limited, Q2 2027 Earnings Call, Nov 06, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GLENMARK PHARMACEUTICALS LIMITED | Generic Pharmaceuticals | -0.62% | -2.25% | +28.58% | +40.02% | +421.92% | 7.91B |
- Stock Market
- Stocks
- GLENMARK Stock
- Charts Glenmark Pharmaceuticals Limited
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
















